-
Mashup Score: 7CTG Labs - NCBI - 14 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7ClinicalTrials.gov - 16 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
@NoopurRajeMD @MGHCancerCenter Bela maf is 1.9 mg/kg q8 weeks, combined with isatuximab, pomalidomide, dexamethasone. So hoping that there will be multiple synergies to maximize efficacy, and spacing out the dosing and decreasing the dose of bela maf to improve the ocular AE profile https://t.co/rB7ZweijsP
-
-
Mashup Score: 1ClinicalTrials.gov - 18 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
🎉 📢Announcement My first investigator-initiated clinical trial, INSPIRE-CRT, is now open for enrollment at MD Anderson Cancer Center at Cooper! @CooperHealthNJ 📄ClinicalTrials link: https://t.co/ABUgFhz8yC We're studying if incentive spirometry can reduce pneumonitis… https://t.co/ZLYCDnz78v https://t.co/6qD3ejUSbY
-
-
Mashup Score: 5ClinicalTrials.gov - 21 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
Initiation visit this morning at @JulesBordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. https://t.co/LGByLBy5E7... #bcsm https://t.co/qVZcH2ovig
-
-
Mashup Score: 6ClinicalTrials.gov - 26 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion. https://t.co/6wFERwFiu7 https://t.co/8EZMsm55Jn
-
-
Mashup Score: 0ClinicalTrials.gov - 29 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet-
🥸 1️⃣1️⃣ The TRISCEND II trial showed TTVR significantly outperformed medical therapy in reducing TR, improving symptoms, and preventing hospitalizations. https://t.co/nAEGD6tjIl
-
-
Mashup Score: 51ClinicalTrials.gov - 1 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet-
No Phase 3 Lp(a) HORIZON started in 2019, and is estimated to read out in 2025. We are almost there...https://t.co/WPN2GejTKH https://t.co/GU4VjeIPnX https://t.co/FZ6zvdbZMW
-
-
Mashup Score: 51ClinicalTrials.gov - 1 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet-
No Phase 3 Lp(a) HORIZON started in 2019, and is estimated to read out in 2025. We are almost there...https://t.co/WPN2GejTKH https://t.co/GU4VjeIPnX https://t.co/FZ6zvdbZMW
-
-
Mashup Score: 3ClinicalTrials.gov - 1 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet-
CLDN18.2 is another emerging target in #PancreaticCancer, highly expressed in ~20%. 2 trials to watch: ⚕️CLAUDIO-01: The CLDN18.2 ADC SOT102. https://t.co/l7jP7ORJ0b ⚕️TWINPEAK: Bi-specific Ab against CLDN18.2 + CD47. https://t.co/tywPYFd146 @SKamath_MD
-
-
Mashup Score: 3ClinicalTrials.gov - 1 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet-
Pan-KRAS inhibition is also an attractive MOA. We're excited at @ClevelandClinic to be part of this phase 1 clinical trial studying PF-07934040 in #PancreaticCancer and other solid tumors. https://t.co/4M7MeLo4ci https://t.co/Li6US1MJNa
-
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUkfVv Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/MbXfQyO9ed